Tumor necrosis factor inhibitor: purification, NH2-terminal amino acid sequence and evidence for anti-inflammatory and immunomodulatory activities - PubMed (original) (raw)

Tumor necrosis factor inhibitor: purification, NH2-terminal amino acid sequence and evidence for anti-inflammatory and immunomodulatory activities

P Seckinger et al. Eur J Immunol. 1990 May.

Abstract

The urine of some febrile patients has been shown to contain a tumor necrosis factor-alpha-inhibiting activity (TNF-alpha INH) when tested in a cytotoxicity assay using the TNF-susceptible cell line L-929. The inhibitor was purified to homogeneity using a simple three-step procedure which included a TNF-alpha affinity column, cation exchange and reverse-phase chromatography. The NH2-terminal amino acid sequence of the inhibitor showed no sequence similarity with proteins in the data bases used. Using gel filtration, it was shown that TNF-alpha and the inhibitor form a stable complex which eluted with a molecular weight of about 75,000. This value corresponds to the sum of the inhibitor (approximately 30,000) and TNF-alpha (approximately 45,000-50,000) molecular weight. The TNF-alpha INH blocked prostaglandin E2 production by dermal fibroblasts in a dose-dependent manner, providing evidence for antiinflammatory activity. TNF-alpha INH also blocked class I antigen expression in a dose-dependent manner as measured using the human Colo 205 tumor cell line. Furthermore, TNF-alpha INH affected TNF-alpha synergism with IFN-gamma-induced HLA-DR antigen expression but had no effect on IFN-gamma activity. The data presented demonstrate that TNF-alpha bioactivity can be regulated at the protein level.

PubMed Disclaimer

Cited by

Clinical review: Myocardial depression in sepsis and septic shock.
Court O, Kumar A, Parrillo JE, Kumar A. Court O, et al. Crit Care. 2002 Dec;6(6):500-8. doi: 10.1186/cc1822. Epub 2002 Sep 12. Crit Care. 2002. PMID: 12493071 Free PMC article. Review.
Regulation of the release of tumour necrosis factor (TNF)alpha and soluble TNF receptor by gamma irradiation and interferon gamma in Ewing's sarcoma/peripheral primitive neuroectodermal tumour cells.
van Valen F, Kentrup-Lardong V, Truckenbrod B, Rübe C, Winkelmann W, Jürgens WW. van Valen F, et al. J Cancer Res Clin Oncol. 1997;123(5):245-52. doi: 10.1007/BF01208634. J Cancer Res Clin Oncol. 1997. PMID: 9201246
LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing.
Screaton GR, Xu XN, Olsen AL, Cowper AE, Tan R, McMichael AJ, Bell JI. Screaton GR, et al. Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4615-9. doi: 10.1073/pnas.94.9.4615. Proc Natl Acad Sci U S A. 1997. PMID: 9114039 Free PMC article.
Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis.
Chikanza IC, Roux-Lombard P, Dayer JM, Panayi GS. Chikanza IC, et al. Clin Exp Immunol. 1993 Apr;92(1):19-22. doi: 10.1111/j.1365-2249.1993.tb05941.x. Clin Exp Immunol. 1993. PMID: 8385584 Free PMC article.
Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines.
Estrov Z, Kurzrock R, Pocsik E, Pathak S, Kantarjian HM, Zipf TF, Harris D, Talpaz M, Aggarwal BB. Estrov Z, et al. J Exp Med. 1993 Mar 1;177(3):763-74. doi: 10.1084/jem.177.3.763. J Exp Med. 1993. PMID: 8382256 Free PMC article.

Tumor necrosis factor inhibitor: purification, NH2-terminal amino acid sequence and evidence for anti-inflammatory and immunomodulatory activities - PubMed (original) (raw)